Chart: Recent And Upcoming FDA Advisory Meetings

Recent And Upcoming FDA Advisory Meetings
Topic	Advisory Committee	Date
Class-wide Risk Evaluation and Mitigation Strategy for opioid drugs	Anesthetic and Life Support Drugs and Drug Safety and Risk Management	July 22-23
AstraZeneca's Brilinta (ticagrelor) for acute coronary syndrome	Cardiovascular and Renal Drugs	July 28
Pfizer's Revatio (sildenafil) for pediatric pulmonary arterial hypertension	Cardiovascular and Renal Drugs	July 29
Valeant Pharmaceuticals North America's Potiga (ezogabine, formerly retigabine) for adjunctive therapy in patients with partial-onset seizures	Peripheral and Central Nervous System Drugs	Aug. 11
Interim report on CDER's pharmacovigilance program; JANUS, the FDA-supported data standard for comparative effectiveness research; FDA's nanotechnology research program	Science Board	Aug. 16
Lilly's Cymbalta (duloxetine HCl) for chronic pain	Anesthetic and Life Support Drugs	Aug. 19
Jazz Pharmaceuticals' sodium oxybate for fibromyalgia in patients age 18 and up	Arthritis and Drug Safety and Risk Management	Aug. 20
Cerexa's ceftaroline fosamil for community-acquired bacterial pneumonia and complicated skin and skin structure infections	Anti-Infective Drugs	Sept. 7
Abuse potential of the cough suppressant dextromethorphan and a Drug Enforcement Administration request for a scheduling recommendation for the drug	Drug Safety and Risk Management	Sept. 14
Statistically significant higher incidence of major cardiovascular adverse events in the Sibutramine Cardiovascular Outcomes Trial of Abbott's obesity drug Meridia (sibutramine)	Endocrinologic and Metabolic Drugs	Sept. 15
Arena's Lorqess (lorcaserin) as an adjunct to diet and exercise for weight management in patients with a body mass index ?30 kg/m^2 or ?27 kg/m^2 with weight-related co-morbidities	Endocrinologic and Metabolic Drugs	Sept. 16
Alkermes' Vivitrol (naltrexone for extended-release injectable suspension) for opioid dependence	Psychpharmacologic Drugs	Sept. 16
Research updates from the Laboratory of Respiratory and Special Pathogens, the Laboratory of Hepatitis Viruses and the Laboratory of Vector Borne Virus Diseases of CBER's Office of Vaccines Research and Review	Vaccines and Related Biological Products	Sept. 21